# Cancer Therapeutics Program

> **NIH NIH P30** · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2024 · $52,379

## Abstract

CANCER THERAPEUTICS PROGRAM: ABSTRACT
The overarching goal of the Cancer Therapeutics (CT) program is to translate discoveries through: 1)
development of new therapeutic agents, 2) biotechnology and bioengineering approaches, and 3) innovative
clinical trials in order to enhance cancer diagnosis and treatment and improve patient outcomes. CT is a new
program in this CCSG application, resulting from the significant growth of clinical and translational research
across solid and hematologic tumors and a strategic realignment of the SCC’s former three programs. It better
positions the SCC for strategically driven growth in these areas and allows for greater catchment area impact.
The CT program is led by Lacey McNally, PhD and Kathleen Moore, MD, who bring complementary
expertise in developing agents and technologies and translating these into clinical trials that can have a
positive impact on patients with cancer.
In 2021, the CT program had 38 members (23 full, 15 associate), representing 13 academic departments at
two campuses (31 at OUHSC; 7 at OU Norman). Of these 38 members, 20 are MDs, underscoring the need to
have a programmatic home within the SCC for clinical trialists and clinician scientists focused in all cancer
types. An additional 75 CT affiliate members (non-CCSG category), including many SCC clinician
investigators, help advance CT program aims. Total peer-reviewed research funding was $6.54M, of which
$4.33M was from NCI (annual, direct cost). Significantly, NCI funding accounts for 66% of total peer-reviewed
funding, highlighting the strong cancer-focus of the CT program. Total peer-reviewed research funding
increased by 29% over the grant cycle ($5.06M to $6.54M), with NCI increasing by 34% ($3.23M to $4.33M).
The number of peer-reviewed projects rose from 23 (2017) to 35 (2021), a 52% increase highlighting
programmatic growth and diversity of research activity. CT members published 755 manuscripts in peer-
reviewed journals over the past five years (3.97 / member / year). Of these, 154 (20%) were intra-
programmatic, 190 (25%) were inter-programmatic, and 570 (75%) were multi-institutional, demonstrating the
high degree of collaboration between CT members, with members in other SCC programs, and with
investigators at other institutions. Importantly, 161 (21%) of CT member publications were published in high-
impact journals (impact factor ≥10). During the reporting period, 3,652 patients were accrued to CT clinical
trials, including 3,095 to interventional treatment trials. The number of annual active CT member interventional
treatment IITs increased from 4 (2017) to 21 (2021), highlighting the expanding depth and breadth of
translational activity emanating from the program.

## Key facts

- **NIH application ID:** 10838556
- **Project number:** 5P30CA225520-07
- **Recipient organization:** UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
- **Principal Investigator:** Lacey R McNally
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $52,379
- **Award type:** 5
- **Project period:** 2018-05-01 → 2028-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10838556

## Citation

> US National Institutes of Health, RePORTER application 10838556, Cancer Therapeutics Program (5P30CA225520-07). Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/grant/nih/10838556. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*